Highlights

  • Tissue Repair (ASX:TRP) is developing TR987, a topical gel for chronic wounds.
  • The Phase 3 TRIVIA trial is evaluating TR987 in patients with chronic venous leg ulcers.
  • Clinical progress and recruitment timelines remain central to the company’s development pathway.
  • Funding requirements continue to be an important consideration for the clinical-stage company.

Tissue Repair Ltd (ASX:TRP) is a clinical-stage biotechnology company developing regenerative medicine technologies. Its lead investigational product, TR987, is a topical gel based on Glucoprime, a beta-glucan-based active ingredient designed to stimulate immune cells involved in wound healing.

The company is initially targeting chronic venous leg ulcers, a type of wound that does not heal through normal recovery processes. The commercial potential of the programme depends on demonstrating that TR987 can improve healing outcomes in controlled clinical studies.

The Phase 3 TRIVIA Trial

The company’s Phase 3 TRIVIA trial is a randomised, double-blind, multicentre study evaluating TR987 alongside standard care compared with standard care alone. The primary endpoint is complete ulcer closure at 16 weeks.

Clinical trial design is important in chronic wound research because healing outcomes can vary between patients and standard care may itself result in wound closure. A controlled study is intended to measure whether TR987 provides additional clinical benefit.

Recruitment progress remains an important operational factor. Delays in enrolment can affect timelines for interim analysis and future clinical milestones.

Commercial Product and Funding Considerations

Tissue Repair also markets TR Pro+, a consumer aftercare gel listed with Australia's Therapeutic Goods Administration and distributed through a commercial partner. However, sales from this product are currently modest compared with the funding requirements of the clinical programme.

The company reported cash of approximately A$8.2 million at 31 December 2025 against quarterly operating outflows of roughly A$2.1 million. Clinical development requires continued funding for research, trials and regulatory activities.

Future Development Milestones

The next important milestones include progress in patient enrolment, completion of interim analysis activities and further clinical evidence regarding TR987’s impact on wound closure.

The company is also pursuing regulatory pathways for TR Pro+ in overseas markets. Progress across clinical and commercial activities will influence the broader development strategy.

Key Insights

Tissue Repair’s current focus is centred on generating clinical evidence for TR987 in chronic wound treatment. The company’s future direction depends on trial execution, funding capacity and whether the therapy demonstrates measurable benefits in controlled studies.